证券记录 · 已归档季度
VRTX
Vertex Pharmaceuticals Incorporated · Healthcare · Biotechnology
19被追踪持有人
-2Δ持有人
60.41M持有股份
$29.28B报告持仓市值
+0新建仓位
−2清仓
动量输入（同类管理人）：
持有人广度 -9.5% ·
股份流向 +0.6% ·
净新建仓位 -10.5%
· 公式
集中增持：持股数量上升，持有人数量减少
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q1 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 1.30M | $664.72M | n/a | −2 |
| Q2 2026 | 173 | -1 | 210.42M | $104.38B | +5 | −7 |
| Q1 2026 | 178 | 0 | 208.95M | $93.29B | +5 | −6 |
| Q4 2025 | 177 | -1 | 219.78M | $99.62B | +2 | −2 |
| Q3 2025 | 26 | +1 | 120.93M | $47.35B | +1 | −1 |
| Q2 2025 | 23 | +1 | 112.15M | $49.92B | +3 | −2 |
| Q1 2025 | 19 | -2 | 60.41M | $29.28B | n/a | −2 |
| Q4 2024 | 21 | +1 | 60.08M | $24.19B | +1 | n/a |
| Q3 2024 | 19 | 0 | 46.24M | $21.49B | n/a | n/a |
| Q2 2024 | 19 | n/a | 46.47M | $21.77B | n/a | n/a |
持有人 · Q1 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Capital World Investors ✦ | 28.53M | +0.7% | $13.83B | 2.2% | ▲ Add | 4 | SEC ↗ |
| 2 | State Street Global Advisors ✦ (被动) | 11.79M | -1.6% | $5.72B | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 3 | Geode Capital Management ✦ (被动) | 5.76M | +2.0% | $2.78B | 0.2% | ▲ Add | 4 | SEC ↗ ×2 |
| 4 | Wellington Management ✦ | 5.45M | -7.8% | $2.64B | 0.5% | ▼ Trim | 4 | SEC ↗ ×8 |
| 5 | Norges Bank ✦ (被动) | 3.36M | -1.5% | $1.63B | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 2.92M | +72.5% | $1.41B | 0.2% | ▲ Add | 4 | SEC ↗ ×2 |
| 7 | Renaissance Technologies ✦ | 1.17M | -16.1% | $568.00M | 0.9% | ▼ Trim | 4 | SEC ↗ |
| 8 | Adage Capital Partners ✦ | 489.67K | +134.0% | $237.40M | 0.4% | ▲ Add | 4 | SEC ↗ |
| 9 | Millennium Management ✦ | 309.94K | -0.2% | $150.26M | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 145.87K | -40.6% | $69.63M | 0.1% | ▼ Trim | 4 | SEC ↗ ×5 |
| 11 | Marshall Wace ✦ | 138.00K | -28.9% | $66.91M | 0.1% | ▼ Trim | 4 | SEC ↗ ×2 |
| 12 | Baillie Gifford ✦ | 134.47K | -10.3% | $65.19M | 0.1% | ▼ Trim | 4 | SEC ↗ ×4 |
| 13 | D. E. Shaw & Co. ✦ | 71.93K | -72.9% | $34.87M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 14 | Tweedy, Browne ✦ | 38.32K | -5.7% | $18.58M | 1.6% | ▼ Trim | 4 | SEC ↗ |
| 15 | Fisher Asset Management ✦ | 30.67K | +2.5% | $14.87M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 16 | Gotham Asset Management ✦ | 27.78K | -7.8% | $13.47M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 17 | ARK Investment Management ✦ | 26.34K | +3.9% | $12.77M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 18 | Citadel Advisors ✦ | 5.02K | -96.9% | $2.43M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 19 | Two Sigma Investments ✦ | 4.12K | -87.6% | $2.00M | 0.0% | ▼ Trim | 4 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| Arrowstreet Capital | $3.73M | 曾为 0.0% |
| Bridgewater Associates | $285,917 | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 1,678 持有人, 225.07M 股份, $98.10B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q1 2025 ·
方法论 ·
通过API获取此数据